Enliven Therapeutics Inc

NASDAQ:ELVNUnited States

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. Its second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations. ELVN-002 is designed to inhibit wild type HER2 and key mutations of HER2, while sparing wild-type EGFR and avoiding EGFR-related toxicities.

Contact Information

Headquarters

6200 Lookout RoadBOULDER, CO, United States 80301

Phone

720-647-8519

Fax

302-655-5049

Executives

Non-Executive Independent Chairman of the Board

Richard Heyman

President, Chief Executive Officer, Director

Sam Kintz

Chief Financial Officer

Benjamin Hohl

Chief Operating Officer

Anish Patel

Chief Scientific Officer, Director

Joseph Lyssikatos